RBCC and n3D Market New iPhone App to Dramatically Shorten Drug Toxicity Testing
NOKOMIS, Fla.--(BUSINESS WIRE)-- Biotech innovator Rainbow Coral Corp. (OTCBB: RBCC) and its joint venture partner Nano3D Biosciences (n3D) are combining on the worldwide marketing and distribution of a new technology that makes testing a drug's potency and toxicity faster and easier.
Nano3D is the developer of a new automated toxicity assay that harnesses the multi-function computing power of the Apple (NAS: AAPL) iPod to test a drug's effects by capturing and charting cell migration data. The Experiment Assistant app, when used with n3D's n3Dock Station and 3D cell culturing technology, organizes and takes time-lapse images of 3D cell culture growth and migration in the presence of a drug.
Through automation, the BiO Assay system can produce drug toxicity results with minimal effort from researchers in 24 hours, in contrast to the 10 days such tests require using current methods.
"The Experiment Assistant app is going to absolutely slash the time necessary to conduct drug testing, which means pharmaceutical companies will soon be able to get their cutting-edge products to the millions who need them faster," said RBCC CEO Patrick Brown. "We're currently consulting with n3D on a worldwide marketing and distribution plan that could make this technology the new standard in testing labs all over the globe."
RBCC formed a biotech subsidiary, Rainbow BioSciences, to market and develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Amgen Inc. (NAS: AMGN) . Rainbow BioSciences acquired an equity interest in n3D earlier last year.
For more information on RBCC's other biotech initiatives, please visit www.rainbowbiosciences.com/investors.html.
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC).The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Rainbow Coral Corp.
Patrick Brown, 850-269-7230
President and CEO
KEYWORDS: United States North America Florida
The article RBCC and n3D Market New iPhone App to Dramatically Shorten Drug Toxicity Testing originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.